Biblio

Author Title [ Type

] Year

Filters: Author is De La Fuente, Josu [Clear All Filters]

Journal Article

Dovern E, Aydin M, Hazenberg MD, Tang MWai, Suijk EM, Hoogendoorn GM, Van Tuijn CFJ, Kerkhoffs J-L, Rutten CE, Zeerleder SS, et al. Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study. Am J Hematol. 2024.

Cseh A, Galimard J-E, De La Fuente J, Isgrò A, Zecca M, Garwer B, Biffi A, Aljurf M, Sundin M, Belendez C, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023.

Wlodarski MW, Vlachos A, Farrar JE, Da Costa LM, Kattamis A, Dianzani I, Belendez C, Ünal Ş, Tamary H, Pasauliene R, et al. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. Lancet Haematol. 2024;11(5):e368-e382.

Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, De La Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, et al. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. N Engl J Med. 2024.

Sureda A, Carpenter PA, Bacigalupo A, Bhatt VRaj, De La Fuente J, Ho A, Kean L, Lee JWook, Sánchez-Ortega I, Savani BN, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024.

Shaw A, Passweg JR, De La Fuente J, Bajwa R, Stein J, Al-Zaben A, Halkes CJM, Norton A, Cummins M, Moppett JP, et al. Relapse of aplastic anemia with majority donor chimerism (donor-type aplasia) occurring late after bone marrow transplantation. Biol Blood Marrow Transplant. 2019.

De La Fuente J, Gluckman E, Makani J, Telfer P, Faulkner L, Corbacioglu S. The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. Lancet Haematol. 2020;7(12):e902-e911.

Krishnamurti L, Arnold SD, Haight A, Abraham A, Guilcher GMt, John T, Bakshi N, Shenoy S, Syrjala K, Martin PL, et al. Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle . JMIR Res Protoc. 2022;11(7):e36780.

Iskander D, Wang G, Heuston EF, Christodoulidou C, Psaila B, Ponnusamy K, Ren H, Mokhtari Z, Robinson M, Chaidos A, et al. Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. Sci Transl Med. 2021;13(610):eabf0113.

Alotaibi H, Aljurf M, de Latour R, Alfayez M, Bacigalupo A, Fakih REl, Schrezenmeier H, Ahmed SOsman, Gluckman E, Iqbal S, et al. Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia W. Transplant Cell Ther. 2021.